三阴性乳腺癌患者应用表阿霉素联合白蛋白结合型紫杉醇治疗的效果观察  

Effect observation of epirubicin combined with albumin-bound paclitaxel in triple-negative breast cancer patients

作　　者：储建 范惠文 唐珊 CHU Jian;FAN Hui-wen;TANG Shan(Department of Thyroid and Breast Surgery,Yancheng First People's Hospital,Yancheng 224000,China)

机构地区：[1]盐城市第一人民医院甲乳外科,224000

出　　处：《中国实用医药》2023年第18期111-114,共4页China Practical Medicine

摘　　要：目的分析三阴性乳腺癌患者应用表阿霉素联合白蛋白结合型紫杉醇治疗的效果。方法100例三阴性乳腺癌患者,按照随机数字表法分成对照组和观察组,每组50例。对照组接受多西紫杉醇和表阿霉素联合治疗,观察组接受表阿霉素和白蛋白结合型紫杉醇联合治疗。对比两组患者临床效果、治疗前后血清学指标及不良反应发生率。结果观察组总有效率98.00%明显高于对照组的80.00%,差异有统计学意义(P<0.05)。治疗前,两组低氧诱导因子-1α(HIF-1α)、内皮素(ET-1)、血管内皮生长因子(VEGF)对比,差异无统计学意义(P>0.05);治疗后,观察组HIF-1α、ET-1、VEGF分别为(128.35±4.74)、(47.73±4.23)、(215.66±6.35)pg/ml,均低于对照组的(142.68±6.43)、(58.36±5.18)、(269.51±7.46)pg/ml,差异有统计学意义(P<0.05)。观察组不良反应发生率18.00%明显低于对照组的44.00%,差异有统计学意义(P<0.05)。结论三阴性乳腺癌患者应用表阿霉素联合白蛋白结合型紫杉醇治疗,不仅临床效果更好,且不良反应比较少,安全性较高,值得临床广泛应用及推广。Objective To analyze the effect of epirubicin combined with albumin-bound paclitaxel in triple-negative breast cancer patients.Methods A total of 100 patients with triple-negative breast cancer were divided into control group and observation group according to random numerical table,with 50 cases in each group.The clinical effect,serological indexes before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of 98.00%in the observation group was significantly higher than that of 80.00%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in hypoxia induction factor-1α(HIF-1α),endothelin(ET-1)and vascular endothelial growth factor(VEGF)between the two groups(P>0.05).After treatment,HIF-1α,ET-1 and VEGF in the observation group were(128.35±4.74),(47.73±4.23)and(215.66±6.35)pg/ml,which were lower than those of(142.68±6.43),(58.36±5.18)and(269.51±7.46)pg/ml in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 18.00%,which was significantly lower than that of 44.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Epirubicin combined with albumin-bound paclitaxel in the treatment of triple-negative breast cancer patients has better clinical effect,less adverse reactions and higher safety,which is worthy of widespread clinical application and promotion.

关 键 词：三阴性乳腺癌 表阿霉素 白蛋白结合型紫杉醇 血清学指标 恶性肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]